US Justice Department Reschedules FDA-Approved and Licensed Medical Marijuana Products to Schedule III
The US Department of Justice and Drug Enforcement Administration announced the immediate reclassification of FDA-approved products containing marijuana and marijuana products regulated by state-issued medical licenses to Schedule III of the Controlled Substances Act. This action aligns with President Trump's Executive Order dated December 18, 2025, aimed at enhancing medical marijuana and cannabidiol research. Alongside this reclassification, the agencies initiated an expedited administrative hearing process scheduled to commence on June 29, 2026. This hearing will evaluate the broader potential rescheduling of marijuana from its current Schedule I classification to Schedule III. These measures provide immediate clarity for medical researchers, patients,... [Continue Reading]
Breaking-360LiveNews | 23 Apr 2026 14:04 LONDON
US reclassifies medical marijuana as less-dangerous Schedule III drug
The US Department of Justice has reclassified state-licensed medical marijuana from Schedule I to Schedule III, marking a significant shift in federal drug policy.This change was announced on April 23, 2026, by Acting Attorney General Todd Blanche under the Trump administration.The reclassification moves medical marijuana from the most restrictive category, Schedule I, reserved for drugs with no accepted medical use and high potential for abuse, to Schedule III, which includes substances with a lower potential for abuse and recognized medical applications.This adjustment does not legalize marijuana federally but changes its regulatory status.The move eases research barriers by allowing scientists to... [Continue Reading]
360LiveNews | 23 Apr 2026 14:03 LONDON
